Home Chevron right People Chevron right Dr Iain Hutcheson
Dr Iain Hutcheson
Teams and roles for Iain Hutcheson
Publication
2021
2014
2011
2010
2009
Elsheikh, S. E. et al., 2009. 162 Altered Histone Modifications and their regulating enzymes in Fulvestrant resistant breast cancer cell line In Vitro [Abstract]. Laboratory Investigation 89 (S1), pp.38A-39A. (10.1038/labinvest.2008.132 )
Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential . Dordrecht: Springer. , pp.63-84. (10.1007/978-1-4020-8526-0_4 )Nicholson, R. I. et al. 2009. Experimental endocrine resistance: concepts and strategies. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential . Dordrecht: Springer. , pp.1-26. (10.1007/978-1-4020-8526-0_1 )Elsheikh, S. E. et al., 2009. Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro [Abstract]. Modern Pathology 22 (S1), pp.38A-39A. 162. (10.1038/modpathol.2008.210 )
Jasani, B. et al. 2009. Resistance to HER2-directed trastuzumab therapy in breast cancer. Advances in Breast Cancer 6 (3), pp.11-18.
2008
Hurtado, A. et al., 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen [Letter]. Nature 456 (7222), pp.663-666. (10.1038/nature07483 )
Bensmail, A. et al. 2008. Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor [Abstract]. Breast Cancer Research 10 (S2) O3. (10.1186/bcr1883 )Hutcheson, I. R. , Gee, J. M. W. and Nicholson, R. I. 2008. MAP Kinase family members and endocrine response and survival in breast cancer. Prognostic and predictive factors in breast cancer. 2nd ed. . London: Informa Healthcare. , pp.122-138. Knowlden, J. M. et al. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111 (1), pp.79-91. (10.1007/s10549-007-9763-9 )Nicholson, R. I. et al. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. Breast cancer: prognosis, treatment and prevention. 2nd ed . London: Informa Healthcare. , pp.123-136.
2007
2006
2005
2004
Nicholson, R. I. et al. 2004. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11 (4), pp.623-641. (10.1677/erc.1.00778 )Hutcheson, I. R. et al. 2004. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment 88 (S1), pp.S145-S146. (10.1007/s10549-004-3602-z )Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 (1), pp.346s-354s. (10.1158/1078-0432.CCR-031206 )Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference . New York: Marcel Dekker. , pp.249-258.
2003
Hutcheson, I. R. et al. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 (1), pp.81-93. (10.1023/A:1025484908380 )Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (3), pp.1032-1044. (10.1210/en.2002-220620 )Britton, D. J. et al., 2003. Oestrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82 (S1), pp.S61. (10.1023/A:1026252325164 )
Hutcheson, I. R. et al. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82 (S1), pp.S170. (10.1023/A:1026252325164 )Nicholson, R. I. et al. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80 (S1), pp.29-34. (10.1023/A:1025467500433 )Clark, J. H. et al. 2003. Expression of adenosine receptors in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 138 , pp.U65. Hutcheson, I. R. , Gee, J. M. W. and Nicholson, R. I. 2003. MAP Kinase family members and endocrine response and survival in breast cancer. Prognostic and Predictive Factors in Breast Cancer . London: Martin Dunitz. , pp.147-166.
2002
Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38 (S7), pp.S59. (10.1016/S0959-8049(02)80835-8 )Nicholson, R. I. , Hutcheson, I. R. and Gee, J. M. W. 2002. Targeting of oestrogen and growth factor signalling pathways in the therapy of breast cancer: Implications for chemoprevention [Abstract]. European Journal of Cancer 38 (S3), pp.S43-S44. (10.1016/S0959-8049(02)81245-X )Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment . Annals of the New York Academy of Sciences Vol. 963.New York: The New York Academy of Sciences. , pp.104-115. (10.1111/j.1749-6632.2002.tb04101.x )Clark, J. H. et al. 2002. Adenosine receptor agonists mediate the phosphorylation of mitogen activated protein kinase (MAPK) in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 135
2001
Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7 (S), pp.3766S. Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8 (3), pp.175-182. (10.1677/erc.0.0080175 )Chaytor, A. et al., 2001. Comparison of alpha and beta isoforms of glycyrrhetinic acid and carbenoxolone as inhibitors of EDHF-type relaxation. Third International Symposium on Endothelium-Derived Hyperpolarizing Factor Vaux de Carnay, France 14-16 June 2000. Published in: Vanhoutte, P. M. ed. EDHF 2000 . London: Taylor and Francis. , pp.115-126. (10.1201/b12802-18 )
1999
1996
Griffith, T. M. , Hutcheson, I. R. and Smith, J. A. 1996. Mechanisms of nitric oxide release from rabbit aorta and their modification by hypercholesterolemia. Functional abnormalities of the aorta . Armonk, NY: Futura Publishing. , pp.69-92.
1995
1994
Griffith, T. M. and Hutcheson, I. R. 1994. Modulation of endothelium-derived relaxing factor activity by flow. Biomechanics and cells . Cambridge: Cambridge University Press. , pp.61-80. Hutcheson, I. R. , Warden-Smith, J. and Griffith, T. M. 1994. Abolition of flow-dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits. British Journal of Pharmacology 113 (1), pp.190-194.
1993
Griffith, T. M. , Edwards, D. and Hutcheson, I. R. 1993. Flow pulsatility, arterial chaos and EDRF activity. Recent Advances in Coronary Circulation: Two Symposia Fukushima, Japan 1993. Published in: Maruyama, Y. et al., Recent Advances in Coronary Circulation: Proceedings of Two Symposia, Fukushima, Japan, 1993 . Tokyo: Springer. , pp.160-170.
1992
Hutcheson, I. R. and Griffith, T. M. 1992. Endothelium-derived relaxing factor release is modulated both by the frequency and amplitude of pulsatile flow. Second International Meeting on the Biology of Nitric Oxide London, UK 1991. Published in: Moncada, S. et al., The Biology of Nitric Oxide, Physiological and Clinical Aspects: Proceedings of the Second International Meeting on the Biology of Nitric Oxide, London, UK, 1991 . London: Portland Press. , pp.161-164.
1991
Boughton-Smith, N. K. et al., 1991. Inflammatory and protective mediators in experimental intestinal inflammation. 60th Falk Symposium Freiburg-im-Breisgau, Germany 18-20 October 1990. Published in: Goebell, H. et al., Inflammatory Bowel Diseases: Progress in Basic Research and Clinical Implications: Proceedings of the 60th Falk Symposium held in Freiburg-im-Breisgau, Germany, October 18-20, 1990 . Falk Symposium Vol. 60. Dordrecht: Kluwer Academic. , pp.137-152.
Griffith, T. M. et al. 1991. Role of flow in endothelial-mediated responses. Third International Symposium on Resistance Arteries Skörping, Denmark 21-25 May 1991. Published in: Mulvaney, M. J. et al., Resistance Arteries: Structure and Function: Proceedings of the Third International Symposium on Resistance Arteries, Rebild, Skörping, Denmark, 21-25 May 1991 . International Congress Series Vol. 974. Amsterdam: Excerpta Medica. , pp.204-207.
Articles
Fakes, L. , Hutcheson, I. and Knowlden, J. 2021. The role of the glucocorticoid receptor in anti-hormone resistance in breast cancer. The British Student Doctor Journal 5 (1), pp.18-31. (10.18573/bsdj.184 )
Gee, J. M. W. et al. 2014. Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer. Cancer Research 74 (19) 738. (10.1158/1538-7445.AM2014-738 )Jordan, N. J. et al. 2014. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Research 16 (1), pp.-. R12. (10.1186/bcr3604 )Hutcheson, I. R. et al. 2011. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research 13 (2) R29. (10.1186/bcr2848 )Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5 (2), pp.67-77. (10.1515/HMBCI.2011.009 )Knowlden, J. M. et al. 2011. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Research 13 (5) R93. (10.1186/bcr3018 )Knowlden, J. M. et al. 2010. O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. EJC Supplements 8 (6), pp.13-14. (10.1016/j.ejcsup.2010.06.037 )Hutcheson, I. R. et al. 2010. Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins [Abstract]. Breast Cancer Research 12 (S1) P13. (10.1186/bcr2510 )Knowlden, J. M. et al. 2010. Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells [Abstract]. Breast Cancer Research 12 (S1), pp.S15. (10.1186/bcr2546 )Thomas, N. B. P. et al., 2010. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Research and Treatment 119 (3), pp.575-591. (10.1007/s10549-009-0355-8 )
Elsheikh, S. E. et al., 2009. 162 Altered Histone Modifications and their regulating enzymes in Fulvestrant resistant breast cancer cell line In Vitro [Abstract]. Laboratory Investigation 89 (S1), pp.38A-39A. (10.1038/labinvest.2008.132 )
Elsheikh, S. E. et al., 2009. Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro [Abstract]. Modern Pathology 22 (S1), pp.38A-39A. 162. (10.1038/modpathol.2008.210 )
Jasani, B. et al. 2009. Resistance to HER2-directed trastuzumab therapy in breast cancer. Advances in Breast Cancer 6 (3), pp.11-18. Hurtado, A. et al., 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen [Letter]. Nature 456 (7222), pp.663-666. (10.1038/nature07483 )
Bensmail, A. et al. 2008. Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor [Abstract]. Breast Cancer Research 10 (S2) O3. (10.1186/bcr1883 )Knowlden, J. M. et al. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111 (1), pp.79-91. (10.1007/s10549-007-9763-9 )Hutcheson, I. R. et al. 2007. Induction of erbB3/EGFR heterodimers mediates resistance to pertuzumab in a tamoxifen-resistant MCF-7 breast cancer cell line [Abstract]. Molecular Cancer Therapeutics 6 (Suppl), pp.3373S. Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9 (4) R50. (10.1186/bcr1754 )Nicholson, R. I. et al. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8 (3), pp.241-253. (10.1007/s11154-007-9033-5 )Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13 (S1), pp.S89-S97. (10.1677/erc.1.01279 )Jones, H. E. et al. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13 (S1), pp.S45-S51. (10.1677/erc.1.01275 )Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96 (2), pp.131-146. (10.1007/s10549-005-9070-2 )Jones, H. E. et al. 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9 (7) e27. (10.1017/S1470903106005451 )Knowlden, J. M. et al. 2005. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146 (11), pp.4609-4618. (10.1210/en.2005-0247 )Nicholson, R. I. et al. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12 (S1), pp.S29-S36. (10.1677/erc.1.00991 )Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93 (2-5), pp.257-262. (10.1016/j.jsbmb.2004.12.006 )Gee, J. M. W. and Hutcheson, I. R. 2005. Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models [Viewpoint]. Breast Cancer Research 7 (5), pp.187-189. (10.1186/bcr1289 )Nicholson, R. I. et al. 2004. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11 (4), pp.623-641. (10.1677/erc.1.00778 )Hutcheson, I. R. et al. 2004. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment 88 (S1), pp.S145-S146. (10.1007/s10549-004-3602-z )Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 (1), pp.346s-354s. (10.1158/1078-0432.CCR-031206 )Hutcheson, I. R. et al. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 (1), pp.81-93. (10.1023/A:1025484908380 )Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (3), pp.1032-1044. (10.1210/en.2002-220620 )Britton, D. J. et al., 2003. Oestrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82 (S1), pp.S61. (10.1023/A:1026252325164 )
Hutcheson, I. R. et al. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82 (S1), pp.S170. (10.1023/A:1026252325164 )Nicholson, R. I. et al. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80 (S1), pp.29-34. (10.1023/A:1025467500433 )Clark, J. H. et al. 2003. Expression of adenosine receptors in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 138 , pp.U65. Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38 (S7), pp.S59. (10.1016/S0959-8049(02)80835-8 )Nicholson, R. I. , Hutcheson, I. R. and Gee, J. M. W. 2002. Targeting of oestrogen and growth factor signalling pathways in the therapy of breast cancer: Implications for chemoprevention [Abstract]. European Journal of Cancer 38 (S3), pp.S43-S44. (10.1016/S0959-8049(02)81245-X )Clark, J. H. et al. 2002. Adenosine receptor agonists mediate the phosphorylation of mitogen activated protein kinase (MAPK) in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 135 Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7 (S), pp.3766S. Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8 (3), pp.175-182. (10.1677/erc.0.0080175 )Hutcheson, I. R. et al. 1999. Nitric oxide independent relaxations to acetylcholine and A23187 involve different routes of heterocellular communication : Role of gap junctions and phospholipase A2. Circulation Research 84 (1), pp.53-63. (10.1161/01.RES.84.1.53 )Pugh, N. D. et al. 1995. Angiographic contrast media relax isolated rabbit aorta through an endothelium-independent mechanism that may not depend on the presence of the iodine atom. British Journal of Radiology 68 (805), pp.23-26. (10.1259/0007-1285-68-805-23 )Hutcheson, I. R. , Warden-Smith, J. and Griffith, T. M. 1994. Abolition of flow-dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits. British Journal of Pharmacology 113 (1), pp.190-194.
Book sections
Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential . Dordrecht: Springer. , pp.63-84. (10.1007/978-1-4020-8526-0_4 )Nicholson, R. I. et al. 2009. Experimental endocrine resistance: concepts and strategies. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential . Dordrecht: Springer. , pp.1-26. (10.1007/978-1-4020-8526-0_1 )Hutcheson, I. R. , Gee, J. M. W. and Nicholson, R. I. 2008. MAP Kinase family members and endocrine response and survival in breast cancer. Prognostic and predictive factors in breast cancer. 2nd ed. . London: Informa Healthcare. , pp.122-138. Nicholson, R. I. et al. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. Breast cancer: prognosis, treatment and prevention. 2nd ed . London: Informa Healthcare. , pp.123-136. Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference . New York: Marcel Dekker. , pp.249-258. Hutcheson, I. R. , Gee, J. M. W. and Nicholson, R. I. 2003. MAP Kinase family members and endocrine response and survival in breast cancer. Prognostic and Predictive Factors in Breast Cancer . London: Martin Dunitz. , pp.147-166. Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment . Annals of the New York Academy of Sciences Vol. 963.New York: The New York Academy of Sciences. , pp.104-115. (10.1111/j.1749-6632.2002.tb04101.x )Griffith, T. M. , Hutcheson, I. R. and Smith, J. A. 1996. Mechanisms of nitric oxide release from rabbit aorta and their modification by hypercholesterolemia. Functional abnormalities of the aorta . Armonk, NY: Futura Publishing. , pp.69-92. Griffith, T. M. and Hutcheson, I. R. 1994. Modulation of endothelium-derived relaxing factor activity by flow. Biomechanics and cells . Cambridge: Cambridge University Press. , pp.61-80.
Conferences
Chaytor, A. et al., 2001. Comparison of alpha and beta isoforms of glycyrrhetinic acid and carbenoxolone as inhibitors of EDHF-type relaxation. Third International Symposium on Endothelium-Derived Hyperpolarizing Factor Vaux de Carnay, France 14-16 June 2000. Published in: Vanhoutte, P. M. ed. EDHF 2000 . London: Taylor and Francis. , pp.115-126. (10.1201/b12802-18 )
Griffith, T. M. , Edwards, D. and Hutcheson, I. R. 1993. Flow pulsatility, arterial chaos and EDRF activity. Recent Advances in Coronary Circulation: Two Symposia Fukushima, Japan 1993. Published in: Maruyama, Y. et al., Recent Advances in Coronary Circulation: Proceedings of Two Symposia, Fukushima, Japan, 1993 . Tokyo: Springer. , pp.160-170. Hutcheson, I. R. and Griffith, T. M. 1992. Endothelium-derived relaxing factor release is modulated both by the frequency and amplitude of pulsatile flow. Second International Meeting on the Biology of Nitric Oxide London, UK 1991. Published in: Moncada, S. et al., The Biology of Nitric Oxide, Physiological and Clinical Aspects: Proceedings of the Second International Meeting on the Biology of Nitric Oxide, London, UK, 1991 . London: Portland Press. , pp.161-164. Boughton-Smith, N. K. et al., 1991. Inflammatory and protective mediators in experimental intestinal inflammation. 60th Falk Symposium Freiburg-im-Breisgau, Germany 18-20 October 1990. Published in: Goebell, H. et al., Inflammatory Bowel Diseases: Progress in Basic Research and Clinical Implications: Proceedings of the 60th Falk Symposium held in Freiburg-im-Breisgau, Germany, October 18-20, 1990 . Falk Symposium Vol. 60. Dordrecht: Kluwer Academic. , pp.137-152.
Griffith, T. M. et al. 1991. Role of flow in endothelial-mediated responses. Third International Symposium on Resistance Arteries Skörping, Denmark 21-25 May 1991. Published in: Mulvaney, M. J. et al., Resistance Arteries: Structure and Function: Proceedings of the Third International Symposium on Resistance Arteries, Rebild, Skörping, Denmark, 21-25 May 1991 . International Congress Series Vol. 974. Amsterdam: Excerpta Medica. , pp.204-207.